H.C. Wainwright raised the firm’s price target on Evolus to $27 from $16 and keeps a Buy rating on the shares post the Q2 results. Jeuveau keeps gaining traction, while Evolysse adds value to the company’s long-term growth strategy, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EOLS: